Hansen Medical Announces 2010 Fourth Quarter and Full-Year Results Conference Call

MOUNTAIN VIEW, CA--(Marketwire - February 08, 2011) - Hansen Medical, Inc. (NASDAQ: HNSN), the global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, announced today that it will release its financial and operating results for the fourth quarter and full year ended December 31, 2010 after market close on Wednesday, February 23, 2011.

Bruce Barclay, president and chief executive officer will host a conference call at 5:00 p.m. ET (2:00 p.m. PT) on February 23, 2011 to discuss the company’s results. The call may be accessed by dialing 877-941-2322 (480-629-9715 for international callers) and via the Internet in the Investor Relations section of Hansen Medical’s website at www.hansenmedical.com. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. Following the call, a webcast replay will be available on Hansen Medical’s website, and an audio replay will also be available by calling 877-870-5176 (858-384-5517 for international callers) and entering the access code 4409948. The audio replay will be available through March 2, 2011.

About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company’s Sensei® system and its Sensei X Robotic Catheter System were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in electrophysiology (EP) procedures. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei and Sensei X systems for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established during EP procedures, such as guiding catheters in the treatment of AF. In the European Union, the Sensei and the Sensei X systems are cleared for use during EP procedures, such as guiding catheters in the treatment of AF, and the Lynx™ robotic catheter is cleared for AF ablation. The Company’s investigational flexible catheter vascular robotic system requires regulatory filings and approval and is not commercially available. Additional information can be found at www.hansenmedical.com.